Biotechnology in the European Union; Trends, Investing & Country Profiles

Product Code PRC00014
Publication Date November 2008
Publisher Pharma-reports
Product Type Report
Pages 91
ISBN Number not applicable
Change currency
PDF £125.00 €151 $198 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

Biotechnology in the European Union; Trends, Investing & Country Profiles

Biotechnology is often considered to be one of the key technologies that will help enable the long-term sustainable development of the European Union (EU), particularly in terms of economic growth, environmental protection and public health. At its March 2000 Lisbon summit the European Council endorsed the objective of making the EU ""the most competitive and dynamic knowledge-based economy in the world, capable of sustainable economic growth with more and better jobs and greater social cohesion"". In 2005 the
Lisbon Strategy was refocused on economic growth and more and better jobs.

The biotechnology products and processes are an integral part of the EU economy, particularly in manufacturing, including pharmaceuticals, agro-food and health care. While some products are invisible to the general public - like use of genetic markers in livestock breeding, etc - others are used on a daily basis - detergents with enzymes and recombinant insulin - or have become a topic of public discussion e.g. genetically modified crops.

The predominance of the health sector in European biotechnology is visible from the distribution of dedicated biotechnology firms by sector. According to Critical I report, 37% of biotechnology companies in 18 European countries (including Norway and Switzerland) were active in the human health care sector while another 18% were classified as active in biodiagnostics, which also includes health care diagnostics. Companies active in agricultural and environmental biotechnology make up 11% of all the biotech companies and 34% of the biotechnology companies provide services such as bioprocessing and screening.

The competitiveness of the EU in developing biotechnology applications depends on the EU's capacity for conducting research, generating new knowledge and converting it into new products and processes. Stimulating research, but also promoting take-up of innovations and encouraging entrepreneurship in biotechnology to reap the economic returns that can be generated from the research results, have been identified as challenges for the EU.

The European biotech industry is investing strongly in the future and is funding large increases in research and development (R&D). R&D expenses have increased by 22% for publicly traded companies and by 15% for the industry as a whole. The industry's longterm growth can only be secured through strong R&D activities. On average, publicly traded European biotech companies are reinvesting about a third of their total revenues in R&D, a strong proof of their dedication to long-term growth. Compared to the beginning of century, many European companies are now better placed to tap into the biotech industry's momentum in the region. Throughout Europe, local governments are striving towards new levels of excellence and the industry overall, is benefiting from focused efforts.

Contents

  • Executive Summary
  • Introduction To Biotechnology
  • Defining Biotechnology
    • History Of Biotechnology
    • Applications Of Biotechnology
  • European Biotechnology Industry
    • Industry Overview
    • Industry Structure
    • Industry Performance
    • Contribution Of Biotechnology To European Industries
    • Growth Of The Industry
    • Market Competitiveness
    • Outlook
  • Industry Trends
    • Patent Application Status
    • Evolving The Research Platform
    • Healthcare & Biotechnology
    • Agriculture & Biotechnology
    • Industrial Biotechnology
    • Marine Biotechnology
    • New Member States
    • Public & Consumer Support For Biotechnology
    • Employment Trends
    • Policy And Regulatory Environment
  • -Investing In The European Biotech Market
    • Overview
    • Investment through Public Equities
    • Investment through Venture Capital
    • Issues in Accessing Finance
    • Financing Start-ups
    • Last-stage Financing
    • Regulatory Measures Required to Improve Access to Finance
  • European Biotech Industry – Country Review
  • Denmark
    • France
    • Germany
    • Netherlands
    • Sweden
    • Switzerland
    • United Kingdom
  • Leading Companies in European Biotech Industry
    • Amgen
    • Bavarian Nordic
    • Élan Corporation
    • Genentech
    • Genmab
    • Genzyme
    • GPC Biotech
    • Innogenetics
    • IsoTis
    • MediGene
    • Medivir Group
    • Protherics
    • Serono
    • Union Chimique Belge
    • Vernalis
    • Vitrolife
  • Case Studies
    • Industrial Biotechnology in UK
    • Overview
    • Market Developments
    • Support for R&D
    • Government Funding for Research
    • Plant Biotechnology for Pest Control
    • Herbicide Tolerant Maize in Europe
    • Virus Resistant Stone Fruit
    • Virus Resistant Tomato
  • Appendix and Glossary
  • List of Figures
  • Figure 1: Distribution of European Biotech Companies by Sub-sector
    • Figure 2: Number of European Biotech Companies per Country
    • Figure 3: Global Share of Biotechnology Patents files at EPO
    • Figure 4: Statistics on European Initial Evaluations (1995-2005)
    • Figure 5: Map of Venture Capital Concentration in Europe
    • Figure 6: Correlation between VC investment and Age of Biotech Company
    • Figure 7: Distribution of Danish Biotech Companies by Segment
    • Figure 8: French Biotech R&D by Industry
    • Figure 9: Investment in French Biotechnology Companies
    • Figure 10: R&D in French Biotech Industry
    • Figure 11: Distribution of German Biotech Companies by Segment
    • Figure 12: Distribution of Dutch Biotech Companies by Segment
    • Figure 13: Distribution of Swedish Biotech Companies by Segment
    • Figure 14: Distribution of Swiss Biotech Companies by Segment
    • Figure 15: Swiss Biotech Clusters
    • Figure 16: Distribution of UK Biotech Companies by Segment
    • Figure 17: Distribution of Biotech Companies in EU by Segment
    • Figure 18: Timeline of Biotechnology
    • Figure 19: Average Turnover per Vaccine in EU (€ million)83
    • Figure 20: Technologies used in Modern Biotechnology
  • List of Tables
  • Table 1: European and International Biotechnology Financing
    • Table 2: Europe's Initial Public Offerings in 2005
    • Table 3: Investment in Denmark's Biotech Sector (2006)
    • Table 4: Selected Private Financing Rounds in 2006
    • Table 5: Top 5 UK Biotech Companies – R&D Investments (2006)
    • Table 6: Genentech's European Revenues (2004-2006)
    • Table 7: Potential Impact of Herbicide Tolerant Maize
    • Table 8: Potential Impact of Virus Resistant Stone Fruit
    • Table 9: Potential Impact of Virus Resistant Tomato
    • Table 10: Top 10 Biopharmaceuticals by Sales
    • Table 11: Contribution of Biotechnology-based Applications to European Economy